Quellenangaben: Tierversuche mit Affen

1 http://www.releasechimps.org/pdfs/chimp-efficacy-paper-main.pdf, Zugriff: 03/2015 

2 http://www.releasechimps.org/pdfs/chimp-efficacy-paper-main.pdf, Zugriff: 03/2015 

3 http://www.safermedicines.org/pdfs/reportbiogenic.pdf, Zugriff: 03/2015 

4 Ellison A., Cowey A. (2009) Differential and co-involvement of areas of the temporal and parietal streams in visual tasks. Neuropsychologia, 47(6), 169-1614. Verfügbar unter http://www.sciencedirect.com/science/article/pii/S0028393208004922, Zugriff: 03/2015 

5 http://cav.asso.fr/en/parkinson.html, , Zugriff: 03/2015 

6 Non-human primates in medical research and drug development_a critical review_Bailey 

7 http://www.parkinson.ch/index.php?id=339, Zugriff: 03/2015 

8 https://www.parkinson-web.de/content/behandlung/nebenwirkungen_der_medikamente/index_ger.html, Zugriff: 03/2015 

9 http://link.springer.com/article/10.1007%2FBF00343235, Zugriff: 03/2015 

10 https://www.parkinson-web.de/content/behandlung/nebenwirkungen_der_medikamente/index_ger.html, Zugriff: 03/2015 

11 http://www.vitanet.de/krankheiten-symptome/morbus-parkinson/therapie/medikamente-l-dopa, Zugriff: 03/2015 

12 http://cav.asso.fr/en/parkinson.html, Zugriff: 03/2015 

13 http://www.leading-medicine-guide.ch/Medizinische-Fachartikel/Tiefe-Hirnstimulation-THS-bei-Parkinson-und-Tremor, Zugriff: 03/2015 

14 http://www.aerzte-gegen-tierversuche.de/de/infos/kosmetik-chemikalien/97-sonstige/802-parkinsonforschung-ohne-tierleid, Zugriff: 03/2015 

15 Innovation Stagnation. Challenge and Opportunity on the Critical Path to New Medical Products. U.S. Department of Health and Human Services. Food and Drug Administration (FDA) (2004). Verfügbar unter http://www.fda.gov/downloads/ScienceResearch/SpecialTopics/CriticalPathInitiative/CriticalPathOpportunitiesReports/UCM113411.pdf, Zugriff: 03/2015 

16 Crawford, Lester M. Speech before PhRMA Annual Meeting. FDA (U.S. Food and Drug Administration) (2004). Verfügbar unter http://www.fda.gov/NewsEvents/Speeches/ucm053576.htm, Zugriff: 03/2015 

17 FDA Drug Review: Postapproval Risks 1975-1985. U.S. General Accounting Office, Washington D.C. (1990). Verfügbar unter http://www.gao.gov/products/PEMD-90-15, Zugriff: 03/2015 

18 Lazarou, J., Pomeranz, B. H. and Corey, P. N. (1998) Incidence of adverse drug reactions in hospitalized patients: A meta-analysis of prospective studies, J. Amer. Med. Assocn. 279, 1200– 1205. Verfügbar unter http://www.ncbi.nlm.nih.gov/pubmed/9555760, Zugriff: 03/2015 

19 http://www.safermedicines.org/primates.shtml, Zugriff: 03/2015 

20 http://www.safermedicines.org/primates.shtml, Zugriff: 03/2015 

21 http://www.ncbi.nlm.nih.gov/pubmed/18826331, Zugriff: 03/2015 

22 http://www.safermedicines.org/primates.shtml, Zugriff: 03/2015 

23 http://www.safermedicines.org/pdfs/reportbiogenic.pdf, Zugriff: 03/2015 

24 Schardein, J. L. (1993) Chemically Induced Birth Defects, 2nd edn. Marcel Dekker, New York. Verfügbar unter http://www.nature.com/jp/journal/v22/n8/full/7210778a.html, Zugriff: 03/2015 

25 Bailey, J., Knight, A. and Balcombe, J. (2005) The future of teratology research is in vitro, Biogenic Amines,19, 97–145.Verfügbar unter http://www.animalliberationfront.com/Philosophy/Animal%20Testing/Vivisection/Jarrod%20Bailey's%20Teratology%20Study%20May%2005.pdf, Zugriff: 03/2015 

26 http://www.pcrm.org/good-medicine/2005/spring/the-next-thalidomide-could-be-just-around-the, Zugriff: 03/2015 

27 http://stemcells.nih.gov/info/basics/pages/basics3.aspx, Zugriff: 03/2015 

28 Kleinstreuer N.C., Yang J., Berg E.L., et. Al (2014) Phenotypic screening of the ToxCast chemical library to classify toxic and therapeutic mechanisms, Nature Biotechnology, 32, 583–591. Verfügbar unter http://www.nature.com/nbt/journal/v32/n6/full/nbt.2914.html, Zugriff: 03/2015 

29 http://www.aerzte-gegen-tierversuche.de/de/infos/tierversuchsfreie-forschung/542-biochips-die-in-vitro-revolution-, Zugriff: 03/2015 

30 http://www.navs.org.uk/about_vivisection/49/71/2522/, Zugriff: 03/2015